• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » New Generic Versions of Naloxone

New Generic Versions of Naloxone

August 1, 2019
Talia Puzantian, PharmD, BCPP.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Talia Puzantian, PharmD, BCPP. Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Naloxone, a rescue medication effective for reversing opioid overdoses, will soon be available in two generic forms for layperson use.

Naloxone nasal spray is the generic version of branded Narcan Nasal, which currently sells for $150 for two doses. The generic version will be much cheaper.

Naloxone auto-injector is the generic version of Evzio auto-injector. The Evzio product costs more than $4000 for two injections, whereas the new generic formulation will be available for $178.

Make sure your patients know about these generic, lower-cost products. You can prescribe them yourself, and in most states pharmacists can also prescribe and dispense this potentially life-saving medication.
Addiction Treatment
KEYWORDS addiction addiction-treatment clinical-practice medication naloxone news_of_note opioid-epidemic opioid-use-disorder opioids overdose pharmacology
    Talia Puzantian, PharmD, BCPP.

    Viloxazine (Qelbree): A Faster Strattera?

    More from this author
    www.thecarlatreport.com
    Issue Date: August 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Legal Issues in Addiction Medicine, CATR, July/August 2019
    Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD
    Can Buprenorphine Improve PTSD Symptoms?
    Opioid Use Disorder: Is There an App for That?
    New Generic Versions of Naloxone
    Treating Addiction in Patients Transitioning to/from Incarceration
    Primer: Confidentiality in Addiction Treatment
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.